

# Thomas Decker

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9007415/publications.pdf>

Version: 2024-02-01

22  
papers

594  
citations

759233

12  
h-index

752698

20  
g-index

22  
all docs

22  
docs citations

22  
times ranked

789  
citing authors

#	ARTICLE	IF	CITATIONS
1	Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin. <i>Blood</i> , 2003, 101, 278-285.	1.4	162
2	Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab. <i>British Journal of Haematology</i> , 2006, 134, 475-484.	2.5	122
3	A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL. <i>Annals of Hematology</i> , 2009, 88, 221-227.	1.8	62
4	Increased number of regulatory T cells (T-regs) in the peripheral blood of patients with Her-2/neu-positive early breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012, 138, 1945-1950.	2.5	34
5	Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase III B 4EVER trial. <i>International Journal of Cancer</i> , 2019, 144, 877-885.	5.1	31
6	VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors – Efficacy, Safety, and Biomarker Results. <i>Clinical Cancer Research</i> , 2022, 28, 3256-3267.	7.0	28
7	Analysis of everolimus starting dose as prognostic marker in HR+ mBC patients treated with everolimus (EVE) + exemestane (EXE): Results of the 3rd interim analysis of the non-interventional trial BRAWO.. <i>Journal of Clinical Oncology</i> , 2017, 35, 1061-1061.	1.6	25
8	Antiapoptotic effect of interleukin-2 (IL-2) in B-CLL cells with low and high affinity IL-2 receptors. <i>Annals of Hematology</i> , 2010, 89, 1125-1132.	1.8	22
9	Effect of Immunostimulatory CpG-Oligonucleotides in Chronic Lymphocytic Leukemia B Cells. <i>Leukemia and Lymphoma</i> , 2001, 42, 301-307.	1.3	21
10	A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO). <i>BMC Cancer</i> , 2017, 17, 499.	2.6	21
11	Significant impact of circulating tumour DNA mutations on survival in metastatic breast cancer patients. <i>Scientific Reports</i> , 2021, 11, 6761.	3.3	16
12	Expression of cyclin E in resting and activated B-chronic lymphocytic leukaemia cells: cyclin E/cdk2 as a potential therapeutic target. <i>British Journal of Haematology</i> , 2004, 125, 141-148.	2.5	13
13	Sensitization of B-cell chronic lymphocytic leukemia cells to recombinant immunotoxin by immunostimulatory phosphorothioate oligodeoxynucleotides. <i>Blood</i> , 2002, 99, 1320-6.	1.4	12
14	VicTORia: a randomised phase II study to compare vinorelbine in combination with the mTOR inhibitor everolimus versus vinorelbine monotherapy for second-line chemotherapy in advanced HER2-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 637-647.	2.5	11
15	The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial. <i>Journal of Bone Oncology</i> , 2019, 14, 100199.	2.4	3
16	Awareness and Availability of Routine Germline BRCA1/2 Mutation Testing in Patients with Advanced Breast Cancer in Germany. <i>Breast Care</i> , 2022, 17, 40-46.	1.4	3
17	The Future Role of PET Imaging in Metastatic Breast Cancer. <i>Oncology Research and Treatment</i> , 2022, 45, 18-25.	1.2	3
18	Clonal Evolution in Patients with Hormone Receptor Positive, HER-2 Negative Breast Cancer Treated with Chemotherapy or CDK4/6 Inhibitors. <i>Oncology Research and Treatment</i> , 2022, 45, 248-253.	1.2	3

#	ARTICLE	IF	CITATIONS
19	Elective Discontinuation of CDK4/6 Inhibitors in Patients with Metastatic Hormone Receptor-Positive, Her-2-Negative Breast Cancer: A Retrospective Single-Center Experience. <i>Oncology Research and Treatment</i> , 2021, 44, 443-449.	1.2	1
20	New Opportunities in Advanced Breast Cancer. <i>Oncology Research and Treatment</i> , 2022, 45, 1-3.	1.2	1
21	Bryostatatin Enhances the Cytotoxic Effects of Anti-CD22 Immunotoxins in CLL by Two Distinct Mechanisms: Implications for a Sequential Therapy.. <i>Blood</i> , 2009, 114, 3429-3429.	1.4	0
22	Recruitment of PKC-Beta to Lipid Rafts Mediates Apoptosis-Resistance in Chronic Lymphocytic Leukemia Expressing Zap-70.. <i>Blood</i> , 2009, 114, 2354-2354.	1.4	0